Inhibition_NN
of_IN
HIV-1_NN
latency_NN
reactivation_NN
by_IN
dehydroepiandrosterone_NN
-LRB-_-LRB-
DHEA_NN
-RRB-_-RRB-
and_CC
an_DT
analog_NN
of_IN
DHEA_NN
._.

The_DT
initial_JJ
infection_NN
with_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
-LRB-_-LRB-
HIV-1_NN
-RRB-_-RRB-
in_IN
most_JJS
individuals_NNS
usually_RB
results_VBZ
in_IN
the_DT
establishment_NN
of_IN
a_DT
latent_JJ
or_CC
chronic_JJ
infection_NN
before_IN
eventual_JJ
progression_NN
toward_IN
acquired_VBN
immunodeficiency_NN
syndrome_NN
._.

HIV-1_NN
can_MD
also_RB
establish_VB
a_DT
latent_JJ
or_CC
persistent_JJ
infection_NN
in_IN
some_DT
T_NN
cell_NN
lines_NNS
that_WDT
show_VBP
minimal_JJ
constitutive_JJ
virus_NN
expression_NN
._.

However_RB
,_,
activation_NN
of_IN
the_DT
T_NN
cell_NN
lines_NNS
leading_VBG
to_TO
enhanced_VBN
HIV-1_NN
replication_NN
can_MD
be_VB
induced_VBN
by_IN
antigens_NNS
,_,
mitogens_NNS
,_,
and_CC
cytokines_NNS
-LRB-_-LRB-
tumor_NN
necrosis_NN
factor_NN
alpha_NN
-LCB-_-LRB-
TNF-alpha_NN
-RCB-_-RRB-
,_,
interleukin_NN
1_CD
,_,
and_CC
interleukin-2_NN
-RRB-_-RRB-
._.

Various_JJ
gene_NN
products_NNS
from_IN
other_JJ
viruses_NNS
-LRB-_-LRB-
HTLV-1_NN
,_,
HSV_NN
,_,
EBV_NN
,_,
CMV_NN
,_,
HBV_NN
,_,
and_CC
HHV-6_NN
-RRB-_-RRB-
can_MD
also_RB
enhance_VB
HIV-1_NN
long_JJ
terminal_JJ
repeat_NN
-LRB-_-LRB-
LTR_NN
-RRB-_-RRB-
-_:
driven_JJ
reporter_NN
gene_NN
activity_NN
._.

On_IN
the_DT
basis_NN
of_IN
these_DT
observations_NNS
,_,
it_PRP
has_VBZ
been_VBN
proposed_VBN
that_IN
reactivation_NN
of_IN
latent_JJ
HIV-1_NN
harbored_VBN
in_IN
chronically_RB
infected_JJ
T_NN
lymphocytes_NNS
,_,
monocytes_NNS
,_,
or_CC
macrophages_NNS
plays_VBZ
an_DT
important_JJ
role_NN
in_IN
the_DT
pathogenesis_NN
of_IN
AIDS_NN
._.

So_RB
far_RB
,_,
there_EX
are_VBP
no_DT
drugs_NNS
or_CC
therapy_NN
available_JJ
that_WDT
can_MD
provide_VB
protection_NN
against_IN
HIV-1_NN
latency_NN
reactivation_NN
._.

ACH-2_NN
,_,
derived_VBN
from_IN
a_DT
human_JJ
T_NN
cell_NN
line_NN
-LRB-_-LRB-
CEM_NN
-RRB-_-RRB-
,_,
is_VBZ
chronically_RB
infected_VBN
with_IN
HIV-1_NN
,_,
with_IN
low_JJ
levels_NNS
of_IN
constitutive_JJ
virus_NN
expression_NN
._.

ACH-2_NN
can_MD
be_VB
converted_VBN
to_TO
productive_JJ
infection_NN
by_IN
stimulation_NN
of_IN
the_DT
cells_NNS
with_IN
12-O-tetradecanoylphorbol-13-acetate_NN
-LRB-_-LRB-
TPA_NN
-RRB-_-RRB-
,_,
mitogen_NN
or_CC
cytokines_NNS
-LRB-_-LRB-
TNF-alpha_NN
-RRB-_-RRB-
,_,
or_CC
infection_NN
with_IN
HSV_NN
._.

Therefore_RB
the_DT
ACH-2_NN
cell_NN
line_NN
is_VBZ
a_DT
good_JJ
candidate_NN
for_IN
studying_VBG
the_DT
effects_NNS
of_IN
drugs_NNS
on_IN
HIV-1_NN
activation_NN
._.

Previously_RB
,_,
we_PRP
have_VBP
reported_VBN
that_IN
DHEA_NN
and_CC
synthetic_JJ
analogs_NNS
of_IN
DHEA_NN
can_MD
be_VB
modest_JJ
inhibitors_NNS
of_IN
HIV-1_NN
IIIB_NN
replication_NN
in_IN
phytohemagglutinin-stimulated_JJ
peripheral_JJ
blood_NN
lymphocyte_NN
cultures_NNS
._.

-LRB-_-LRB-
ABSTRACT_NN
TRUNCATED_VBN
AT_IN
250_CD
WORDS_NNS
-RRB-_-RRB-

